Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA.
Clinical and Translational Institute, University of California Los Angeles, Los Angeles, CA.
J Low Genit Tract Dis. 2023 Jul 1;27(3):193-197. doi: 10.1097/LGT.0000000000000755. Epub 2023 Jun 6.
To evaluate single-pass loop electrosurgical excision procedure (LEEP-SP) versus LEEP with top hat (LEEP-TH) in terms of treatment failure defined as high-grade squamous intraepithelial lesion (HSIL) cytology within 2 years' follow-up.
This single-institution cohort study used a prospectively collected cervical dysplasia database including all patients who underwent LEEP-SP or LEEP-TH for biopsy-proven cervical intraepithelial neoplasia between 2005 and 2019.
Of 340 patients included, 178 underwent LEEP-SP and 162 LEEP-TH. The LEEP-TH patients were more likely to be older (mean age, 40.4 vs 36.5 years; p < .001) and have a positive preprocedure endocervical sampling (68.5% vs 11.8%; p < .001). Positive margins were found in 23 LEEP-SP (12.9%) and in 25 LEEP-TH (15.4%; p = .507). There was no significant difference in depth of excision between LEEP-SP (13.21 ± 23.19 mm) and LEEP-TH (17.37 ± 28.26 mm; p = .138). At 2 years, there was no difference in the rates of HSIL cytology (5.2% vs 6.3%; p = .698), any positive human papillomavirus test, or HSIL cytology (25% vs 15%; p = .284). The 57 patients undergoing repeat excision were more likely to be older (mean age, 40.95 vs 37.52 years; p = .023), have had a LEEP-TH (26.3% vs 73.7%; p < .001), and have initial cytologic HSIL (64.9% vs 35.0%; p < .001).
In this single-institution study, there is no difference in the rate of recurrent HSIL in patients undergoing LEEP-SP versus LEEP-TH. A LEEP-TH may have limited additional benefit over a LEEP-SP in the treatment of cervical HSIL.
评估单次环型电切术(LEEP-SP)与使用帽状环型电切术(LEEP-TH)在 2 年随访期间定义为高级别鳞状上皮内病变(HSIL)细胞学治疗失败方面的情况。
这项单机构队列研究使用了一个前瞻性收集的宫颈发育不良数据库,包括 2005 年至 2019 年间因活检证实的宫颈上皮内瘤变而接受 LEEP-SP 或 LEEP-TH 的所有患者。
340 例患者中,178 例行 LEEP-SP,162 例行 LEEP-TH。LEEP-TH 患者年龄更大(平均年龄,40.4 岁比 36.5 岁;p <.001),术前宫颈取样呈阳性(68.5%比 11.8%;p <.001)的可能性更大。LEEP-SP 中有 23 例(12.9%)和 LEEP-TH 中有 25 例(15.4%)边缘阳性(p =.507)。LEEP-SP(13.21 ± 23.19 mm)和 LEEP-TH(17.37 ± 28.26 mm;p =.138)之间切除深度无显著差异。2 年后,HSIL 细胞学(5.2%比 6.3%;p =.698)、任何阳性人乳头瘤病毒检测或 HSIL 细胞学(25%比 15%;p =.284)的发生率无差异。57 例再次接受切除术的患者年龄更大(平均年龄,40.95 岁比 37.52 岁;p =.023),接受 LEEP-TH(26.3%比 73.7%;p <.001)和初始细胞学 HSIL(64.9%比 35.0%;p <.001)的可能性更大。
在这项单机构研究中,LEEP-SP 与 LEEP-TH 治疗宫颈 HSIL 后 HSIL 复发率无差异。LEEP-TH 在治疗宫颈 HSIL 方面可能比 LEEP-SP 仅具有有限的额外益处。